Journal of Clinical Oncology

Vol. 43, Issue 32 Issue 32 2025
17
Articles

Articles in this Issue

Reply to: Response to Neoadjuvant Chemotherapy and Breast Cancer Subtypes

David J. Winchester Nov 10, 2025 pp. 3545-3546 10.1200/jco-25-01972

Erratum: Efficacy and Safety of Avutometinib ± Defactinib in Recurrent Low-Grade Serous Ovarian Cancer: Primary Analysis of ENGOT-OV60/GOG-3052/RAMP 201

Susana N. Banerjee, Els Van Nieuwenhuysen, Carol Aghajanian et al. Nov 10, 2025 pp. 3547-3547 10.1200/jco-25-02377

Deep Learning Model for Breast Shear Wave Elastography to Improve Breast Cancer Diagnosis (INSPiRED 006): An International, Multicenter Analysis

Lie Cai, André Pfob, Richard G. Barr et al. Nov 10, 2025 pp. 3482-3493 10.1200/jco-24-02681

PURPOSE Shear wave elastography (SWE) has been investigated as a complement to B-mode ultrasound for breast cancer diagnosis. Although multicenter trials suggest benefits for patie...

Recurrence Patterns of Esophageal Adenocarcinoma in the Phase III ESOPEC Trial Comparing Perioperative Chemotherapy With Preoperative Chemoradiotherapy

Jens Hoeppner, Claudia Schmoor, Thomas Brunner et al. Nov 10, 2025 pp. 3451-3456 10.1200/jco-25-00948

The ESOPEC trial showed that perioperative chemotherapy with fluorouracil (FU)/leucovorin/oxaliplatin/docetaxel (FLOT) improved survival in patients with nonmetastatic esophageal adenocarcinoma compar...

End Points for the Next-Generation Bladder-Sparing Perioperative Trials for Patients With Muscle-Invasive Bladder Cancer

Andrea Necchi, Matthew D. Galsky, Nazli Dizman et al. Nov 10, 2025 pp. 3536-3544 10.1200/jco-25-01608

PURPOSE The evolving treatment landscape of muscle-invasive bladder cancer (MIBC) increasingly warrants novel trial design to evaluate perioperative strategies aimed at bladder pre...

Efficacy and Safety of BL-B01D1 in Patients With Locally Advanced or Metastatic Urothelial Carcinoma: A Phase II Clinical Trial

Xiaojie Bian, Tiejun Yang, Huaqi Yin et al. Nov 10, 2025 pp. 3505-3515 10.1200/jco-25-00109

PURPOSE To evaluate the efficacy and safety of BL-B01D1, a potential first-in-class epidermal growth factor receptor (EGFR)–human EGFR 3 bispecific antibody-drug conjugated (ADC) w...

Inotuzumab Ozogamicin Then Blinatumomab for Older Adults With Newly Diagnosed B-Cell ALL: Alliance Study A041703 Cohort 1 Results

Matthew J. Wieduwilt, Jun Yin, Oudom Kour et al. Nov 10, 2025 pp. 3526-3535 10.1200/jco-25-00307

PURPOSE Older patients with ALL receiving conventional chemotherapy have poor survival due to toxic death and relapse. We hypothesized that a chemotherapy-free, targeted regimen us...

Precision Oncology and Modernizing Evidence Standards: A Critical Commentary on the Cochrane Review

Vivek Subbiah, Razelle Kurzrock Nov 10, 2025 pp. 3446-3450 10.1200/jco-25-01475

Bringing Trustworthy Artificial Intelligence to the Clinical Forefront at <i>JCO</i> : A Guide for Studies Testing Artificial Intelligence Models

Ravi B. Parikh, Alexia Iasonos, Andrew Ko et al. Nov 10, 2025 pp. 3434-3438 10.1200/jco-25-01939

Development and Validation of an Artificial Intelligence Digital Pathology Biomarker to Predict Benefit of Long-Term Hormonal Therapy and Radiotherapy in Men With High-Risk Prostate Cancer Across Multiple Phase III Trials

Andrew J. Armstrong, Vinnie Y.T. Liu, Ramprasaath R. Selvaraju et al. Nov 10, 2025 pp. 3494-3504 10.1200/jco.24.00365

PURPOSE Long-term androgen deprivation therapy (ADT) improves survival in men with high-risk localized prostate cancer (PCa) receiving radiotherapy (RT). Predictive biomarkers are...

Bridging the Gap: The Evolving Landscape of CNS Management in Small Cell Lung Cancer: Prophylactic Cranial Irradiation in the Modern Era

Tafadzwa L. Chaunzwa, Salma K. Jabbour, Luke R.G. Pike et al. Nov 10, 2025 pp. 3439-3445 10.1200/jco-25-01817

Foundation Model for Predicting Prognosis and Adjuvant Therapy Benefit From Digital Pathology in GI Cancers

Xiyue Wang, Yuming Jiang, Sen Yang et al. Nov 10, 2025 pp. 3468-3481 10.1200/jco-24-01501

PURPOSE Artificial intelligence (AI) holds significant promise for improving cancer diagnosis and treatment. Here, we present a foundation AI model for prognosis prediction on the...

Response to Neoadjuvant Chemotherapy and Breast Cancer Subtypes

Miguel Martín Nov 10, 2025 pp. 3545-3545 10.1200/jco-25-01342

Apples, Oranges, and ESOPEC Recurrence Patterns

Matthew R. Strickland, Theodore S. Hong, Samuel J. Klempner Nov 10, 2025 pp. 3429-3433 10.1200/jco-25-01552

Erratum: Identifying Patients With Low Relapse Rate Despite High-Risk Estrogen Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Early Breast Cancer: Development and Validation of a Clinicopathologic Assay

François-Clément Bidard, Grégoire Gessain, Thomas Bachelot et al. Nov 10, 2025 pp. 3547-3547 10.1200/jco-25-02272

Hippocampal Avoidance During Prophylactic Cranial Irradiation for Patients With Small Cell Lung Cancer: Randomized Phase II/III Trial NRG-CC003

Vinai Gondi, Stephanie L. Pugh, Minesh P. Mehta et al. Nov 10, 2025 pp. 3516-3525 10.1200/jco-25-00221

PURPOSE Hippocampal avoidance (HA) during therapeutic whole-brain radiotherapy reduces the risk of neurocognitive function (NCF) toxicity in patients with brain metastasis. This tr...

Neoadjuvant CTLA-4/PD-(L)1 Blockade Versus Surgery +/− Chemotherapy in Deficient Mismatch Repair/Microsatellite Instability–High Resectable Gastroesophageal Adenocarcinoma: Individual Patient Data Pooled Analysis

Alessandra Raimondi, Gabriele Tinè, Alexej Ballhausen et al. Nov 10, 2025 pp. 3457-3467 10.1200/jco-25-00447

PURPOSE Patients with deficient mismatch repair (dMMR)/microsatellite instability-high (MSI-H) resectable gastroesophageal adenocarcinoma (GEA) have better survival after surgery a...

All Issues

Journal Info

Publisher Lippincott Williams & Wilkins
ISSN 0732-183X
E-ISSN 1527-7755
Subject Health Sciences
Language English
View Full Journal Page